-
TLR4: Unraveling the Role of Inflammation in Cancer Progression(Post)
Introduction to TLR4 and Cancer Toll-like receptor 4 (TLR4) is a key component of the innate immune system, primarily responsible for detecting infections and initiating inflammatory resp
Tocilizumab: Advancing Therapeutics and Research with Biosimilars(Post)What You Need to Know About TocilizumabWhat is Tocilizumab?Tocilizumab is a monoclonal antibody that targets the interleukin-6 (IL-6) receptor, widely used for managing autoimmune and in
Tidutamab: Unlocking the Potential of SSTR2-Targeting in Oncology Research(Post)Quick Facts About TidutamabWhat is Tidutamab?Tidutamab is a monoclonal antibody designed to target somatostatin receptor 2 (SSTR2), a key protein involved in various neuroendocrine tumor
CAR-T Cell Signalling Pathway: Costimulation, Output and Assays(Post)A chimeric antigen receptor is a synthetic protein wired into a real signalling pathway. The extracellular half is an antibody fragment; everything below the membrane is borrowed from the T-cell rece
After Tocilizumab, IL-6 Goes Up. That Is the Drug Working.(Post)Tocilizumab reverses cytokine release syndrome within hours, and it never touches the cell that started it. That sentence contains the whole mechanism. The trigger is a T cell — engaged by a CAR, a b
The Adenosine Axis: How CD39 and CD73 Switch Immunity Off(Post)The most abundant immunosuppressive molecule in a solid tumour is not a protein. It is adenosine — a metabolite, produced from ATP in two enzymatic steps, at concentrations orders of magnitude above
Unconventional T Cells: Gamma Delta, iNKT and MAIT(Page) Platelet Adhesion Proteins and Ligands: Key Players in Hemostasis and Thrombosis(Post)Platelet adhesion is a critical process in the maintenance of hemostasis, the body's response to bleeding. This intricate process involves a series of interactions between platelets, the cellular
T-Cell Engagers: Signal 1 Without Signal 2(Post)A T-cell engager does not give the T cell an instruction. It gives it an address. A bispecific antibody with one arm on CD3 and the other on a tumour antigen forces two membranes into contact and let
Basiliximab: Mechanism, Clinical Applications, and Research Advancements(Post)Quick Facts About BasiliximabWhat is Basiliximab?Basiliximab is a monoclonal antibody targeting the CD25 subunit of the IL-2 receptor, primarily used to prevent organ transplant rejectio
Lirilumab: Unlocking the Potential of Anti-KIR Therapy in Cancer Research(Post)Quick Facts About LirilumabWhat is Lirilumab?Lirilumab is an anti-KIR monoclonal antibody designed to enhance natural killer (NK) cell activity by blocking killer-cell immunoglobulin-lik
Interactive Pathway Diagrams(Page) Vascular Endothelial Growth Factor A (VEGFA): A Cornerstone in Angiogenesis and Beyond(Post)Vascular Endothelial Growth Factor A (VEGFA) is a pivotal signaling protein involved in both vasculogenesis and angiogenesis, processes essential for the formation of blood vessels during embryoni
Apoptosis Pathway(Page) SLAMF7: Activating Natural Killer Cells for Potent Anti-Cancer Responses(Post)Introduction to SLAMF7 in Cancer Immunotherapy SLAMF7, also known as Signaling Lymphocytic Activation Molecule F7, is a surface receptor found on natural killer (NK) cells, T cells, plasm
Farletuzumab: Advancing Antibody-Drug Conjugate Research in Ovarian Cancer(Post)Quick Facts About FarletuzumabWhat is Farletuzumab?Farletuzumab is a humanized monoclonal antibody targeting folate receptor alpha (FRα), a protein overexpressed in ovarian and other epi
CD8+ T Cells: Understanding the Role of Cytotoxic T Cells in Immunity(Post)Immunology · T LymphocytesCD8+ T Cells: Cytotoxic Mechanisms, Memory and ExhaustionCD8+ T cells kill infected and transformed cells directly, and they do it with a specificity nothing else in the immu
Anti-Angiogenics Do Not Starve Tumours. They Open Them.(Post)Anti-angiogenic therapy does not work by starving tumours, and the trials that assumed it did are the reason the field spent a decade disappointed. Cutting off the blood supply was the original pitch
T-Cell Co-Stimulation & Agonist Checkpoint Pathway(Page) KIR Blockade: Empowering NK Cells for Superior Tumor Clearance(Post)Introduction to KIR Blockade in Cancer ImmunotherapyNatural killer (NK) cells are crucial components of the innate immune system, responsible for recognizing and destroying virally infec
Top 10 Therapeutics(Page) The Interferon Axis: Type I vs Type II Signalling Explained(Post)Both interferon families run through STAT1, and that single shared subunit is why they are so often conflated — and why conflating them is a mistake. Type I interferon assembles STAT1 into a three-pa
NF-κB Signalling Pathway(Page) Interferon Axis — Type I & Type II Signalling(Page) Antigen Processing & Presentation(Page) TNFRSF9: Enhancing Immune Cell Activity Against Tumors(Post)Introduction to TNFRSF9 and Its Role in Immune ActivationTNFRSF9, also known as 4-1BB or CD137, is a co-stimulatory receptor expressed on the surface of T cells, natural killer (NK) cells
T-Cell Co-Stimulation and Agonist Checkpoint Signalling Explained(Post)Signal 1 tells a T cell what it is looking at; signal 2 tells it whether to care. The same peptide–MHC engagement that launches a productive effector response can just as easily install an anergy pro
B-cell activation and the germinal centre reaction(Page) CD28: Amplifying T Cell Responses for Better Tumor Clearance(Post)The CD28 molecule plays a crucial role in amplifying T cell activation, which is critical for mounting effective immune responses against tumors. By engaging with co-stimulatory molecules
Tarextumab: Unlocking the Potential of Cancer Therapeutics(Post)Quick Facts About TarextumabWhat is Tarextumab?Tarextumab is a novel therapeutic antibody designed to target the Notch signaling pathway, which plays a crucial role in tumor progression
Thymic T-Cell Development & Central Tolerance(Page) TREM2: Exploring Its Role in Tumor-Associated Macrophages and Cancer Immunotherapy(Post)Introduction to TREM2 and Tumor-Associated Macrophages in CancerTREM2 (triggering receptor expressed on myeloid cells 2) is an immunoregulatory receptor primarily expressed on macrophages
Varlilumab: Unlocking CD27’s Potential in Cancer Research(Post)What You Need to Know About VarlilumabWhat is Varlilumab?Varlilumab is a monoclonal antibody targeting CD27, a receptor on T-cells that plays a critical role in immune modulation.What is
Tigatuzumab: Advancing Cancer Research with Targeted Therapies(Post)Quick Facts About TigatuzumabWhat is Tigatuzumab?Tigatuzumab is a monoclonal antibody that targets the death receptor 5 (DR5) pathway, inducing apoptosis in cancer cells.What is the mech
PVR: Balancing Immune Activation and Suppression in Cancer(Post)PVR (Poliovirus receptor), also known as CD155, is a molecule that plays a dual role in regulating the immune response within the tumor microenvironment. While initially discovered as a r
Tumour Angiogenesis and the VEGF Axis(Page) Cytokine ELISA Kits(Page)High Sensitivity Cytokine ELISA Kits & Multiplex Panels | Assay Genie
IgE and Mast Cells: The Cell Is Armed in Advance(Post)The mast cell is loaded long before the allergen arrives. IgE bound to FcεRIα is not waiting to be recruited the way an antibody waits for antigen in a serum assay — it is already installed on the ce
Ifabotuzumab: Exploring the Role of Anti-EphA3 in Cancer Research(Post)What You Need to Know About IfabotuzumabWhat is Ifabotuzumab?Ifabotuzumab is a monoclonal antibody targeting EphA3, a receptor tyrosine kinase overexpressed in certain cancers. It plays
Bcell germinal centre pathway(Page) Nfkb signalling pathway · HTM(Page) Bococizumab: Mechanism, Clinical Applications, and Biosimilars in Research(Post)Quick Facts About BococizumabWhat is Bococizumab?Bococizumab is a monoclonal antibody that targets PCSK9, a protein involved in cholesterol regulation.How Does Bococizumab Work?It inhibi
TAM and MDSC Signalling: Myeloid Reprogramming Pathway Guide(Post)In most solid tumours the largest immune population is not a T cell. It is a myeloid cell that has been recruited, expanded and re-educated by the tumour itself. Tumour-associated macrophages and mye
Enavatuzumab: Revolutionizing Cancer Research Through Novel Therapeutics(Post)Quick Facts About EnavatuzumabWhat is Enavatuzumab?Enavatuzumab is a monoclonal antibody targeting the TWEAK receptor (Fn14), pivotal in tumor growth and immune regulation.What is the me
Cell-Based ELISA Kits (Page)Cell-Based ELISA Kits | 1,600+ Total & Phospho Targets | Assay Genie
Unconventional T Cells: Already Armed, and No MHC Required(Post)Most immunology is written as though a T cell must first be told what to look for. Three lineages did not read that memo. γδ T cells, invariant NKT cells and MAIT cells leave the thymus with their ef
Antigen Processing and Presentation: MHC-I, MHC-II, Cross-Priming(Post)Every T-cell response begins with a protein being taken apart. Before a CD8 or CD4 T cell can see anything, an antigen has to be degraded into peptides of the right length, delivered to the right com
Mogamulizumab: Understanding Its Mechanism, Clinical Applications, and the Role of Biosimilars in Research(Post)Quick Info Section: Key Facts About MogamulizumabWhat is Mogamulizumab?Mogamulizumab is an anti-CCR4 monoclonal antibody used primarily for treating certain cancers, including cutaneous
Mucosal Homing and Tissue-Resident Memory(Page) DNA Origami in the Brain: How Nanoscale Structural Folding Governs Neural Development(Post)Imagine a world where we can fold the very fabric of life into microscopic machines, guiding the growth of a single neuron with the precision of a master architect. This isn't science fiction; it is
Treg Suppression and the IL-2 Axis: Pathway, Function and Assays(Post)Regulatory T cells cannot make the cytokine they depend on. FOXP3 represses the Il2 locus, so every Treg lives on IL-2 secreted by the conventional T cells it exists to restrain. That asymmetry expla
Adaptive immune system molecules(Page) High Sensitivity Cytokine ELISA Kits & Multiplex Panels(Page)High Sensitivity Cytokine ELISA Kits & Multiplex Panels | Assay Genie
BTLA: A Key Player in Immune Regulation and Cancer Therapy(Post)Introduction to BTLA in Immune Regulation B and T lymphocyte attenuator (BTLA) is an immune checkpoint molecule that plays a critical role in regulating immune responses by suppressing T
Innate Lymphoid Cells Differentiation: Guardians of Immune Homeostasis(Post)Innate Lymphoid Cells (ILCs) represent a fascinating component of the immune system, playing a crucial role in maintaining tissue homeostasis and mounting rapid responses against pathogens. The
Two Asthma Drugs, Opposite Eosinophil Counts, Both Working(Post)Two asthma biologics have opposite effects on the blood eosinophil count, and both of them work. Mepolizumab empties the eosinophil compartment; dupilumab can transiently raise it. If that seems cont
Ramucirumab: Mechanism, Clinical Applications, and Biosimilars in Cancer Research(Post)Quick Facts About RamucirumabWhat is Ramucirumab?Ramucirumab is a monoclonal antibody that targets vascular endothelial growth factor receptor 2 (VEGFR-2), inhibiting angiogenesis, a pro
CAR-T cell signalling(Page) Blood Coagulation Signaling Pathways: A Critical Overview(Post)Cell Signalling · HaemostasisBlood Coagulation Signaling Pathways: A Critical OverviewBlood coagulation is a tightly regulated cascade in which circulating clotting factors are sequentially activated
Antibody Light Chains, Heavy Chains, Constant Regions & Tumour-Associated Antigens(Post)Immunology · Antibody BiologyAntibody Light Chains, Heavy Chains, Constant Regions & Tumour-Associated AntigensAn antibody’s specificity comes from its variable domains and its biological effect comes
Patritumab Deruxtecan: Mechanism, Clinical Applications, and Biosimilar Advances(Post)Quick Facts About Patritumab DeruxtecanWhat is Patritumab Deruxtecan?Patritumab Deruxtecan (HER3-DXd) is an investigational antibody-drug conjugate (ADC) targeting HER3, a receptor impli
Dupilumab: Transforming Immunotherapy and Skin Disease Management(Post)What You Need to Know About DupilumabWhat is Dupilumab?Dupilumab is a fully human monoclonal antibody designed to treat various chronic inflammatory diseases by inhibiting key cytokines
Exploring the Frontier of Immunotherapy: T Cell Expansion(Post)In the realm of immunotherapy, T cell expansion has emerged as a pivotal strategy, holding promise in the treatment of various diseases, particularly cancer. T cells are a critical component of
Cetuximab: A Revolutionary Drug in Cancer Therapy(Post)Quick Facts About CetuximabWhat is Cetuximab?Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), widely used in cancer therapy.How does Cetuximab wor
B-Cell Depletion and the BAFF-APRIL Axis(Page) Monalizumab: A Breakthrough in Cancer Immunotherapy Targeting NKG2A(Post)Quick Facts About MonalizumabWhat is Monalizumab?Monalizumab is a first-in-class immune checkpoint inhibitor targeting NKG2A, developed to enhance anti-tumor immune response by blocking
Denosumab: A Comprehensive Overview of Mechanism, Applications, and Research Advances(Post)Biologics · Bone MetabolismDenosumab: RANKL Inhibition, Clinical Applications and BiosimilarsDenosumab is a fully human monoclonal antibody against RANKL, the cytokine that drives osteoclast formation
Vixarelimab: A Novel Approach to Targeting Prurigo Nodularis and Fibrosis(Post)Quick Facts About VixarelimabWhat is Vixarelimab?Vixarelimab is an investigational monoclonal antibody developed to target oncostatin M receptor beta (OSMRβ), a key pathway involved in p
Microglia and Neuroinflammation(Page) Leukocyte Adhesion Cascade(Page) Understanding Platelet Activation: A Comprehensive Overview(Post)Haemostasis · Platelet BiologyUnderstanding Platelet Activation: A Comprehensive OverviewPlatelet activation is the rapid, tightly controlled response by which circulating platelets change shape, rele
LAG-3: Revitalizing T Cells in Exhaustion for Combination Therapies(Post)Lymphocyte Activation Gene-3 (LAG-3) is an immune checkpoint receptor that plays a critical role in regulating T cell function. In recent years, LAG-3 has emerged as a potential target fo